» Articles » PMID: 35963558

Methylphenidate, Guanfacine, and Combined Treatment Effects on Electroencephalography Correlates of Spatial Working Memory in Attention-Deficit/Hyperactivity Disorder

Overview
Publisher Elsevier
Specialties Pediatrics
Psychiatry
Date 2022 Aug 13
PMID 35963558
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The combination of d-methylphenidate and guanfacine (an α-2A adrenergic agonist) may be an effective alternative to either agent as monotherapy in children with attention-deficit/hyperactivity disorder (ADHD). This study investigated the neural mechanisms underlying medication effects using cortical source analysis of electroencephalography (EEG) data.

Method: A total of 172 children with ADHD (aged 7-14; 118 boys) completed an 8-week randomized, double-blind, comparative study with 3 treatment arms: d-methylphenidate, guanfacine, or their combination. EEG modulations of brain oscillations at baseline and end point were measured during a spatial working memory task from cortical sources localized within the anterior cingulate (midfrontal) and primary visual cortex (midoccipital), based on previously reported ADHD and control differences. Linear mixed models examined treatment effects on EEG and performance measures.

Results: Combined treatment decreased midoccipital EEG power across most frequency bands and task phases. Several midoccipital EEG measures also showed significantly greater changes with combined treatment than with monotherapies. D-methylphenidate significantly increased midoccipital theta during retrieval, while guanfacine produced only trend-level reductions in midoccipital alpha during maintenance and retrieval. Task accuracy improved with combined treatment, was unchanged with d-methylphenidate, and worsened with guanfacine. Treatment-related changes in midoccipital power correlated with improvement in ADHD severity.

Conclusion: These findings show that combined treatment ameliorates midoccipital neural activity associated with treatment-related behavioral improvements and previously implicated in visuo-attentional deficits in ADHD. Both monotherapies had limited effects on EEG measures, with guanfacine further showing detrimental effects on performance. The identified midoccipital EEG profile may aid future treatment monitoring for children with ADHD.

Clinical Trial Registration Information: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder (Project1); https://clinicaltrials.gov/; NCT00429273.

Diversity & Inclusion Statement: We worked to ensure race, ethnic, and/or other types of diversity in the recruitment of human participants. We worked to ensure sex and gender balance in the recruitment of human participants. One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented racial and/or ethnic groups in science. While citing references scientifically relevant for this work, we also actively worked to promote sex and gender balance in our reference list. We actively worked to promote inclusion of historically underrepresented racial and/or ethnic groups in science in our author group. We actively worked to promote sex and gender balance in our author group.

Citing Articles

Prefrontal Transcranial Direct Current Stimulation in Pediatric Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

Krauel K, Brauer H, Breitling-Ziegler C, Freitag C, Luckhardt C, Muhlherr A JAMA Netw Open. 2025; 8(2):e2460477.

PMID: 39982727 PMC: 11846015. DOI: 10.1001/jamanetworkopen.2024.60477.


Decreased impulsiveness and MEG normalization after AI-digital therapy in ADHD children: a RCT.

Bilan D, Chicchi Giglioli I, Cuesta P, Canadas E, de Ramon I, Maestu F Npj Ment Health Res. 2025; 4(1):1.

PMID: 39779908 PMC: 11711623. DOI: 10.1038/s44184-024-00111-9.


Translating Decades of Neuroscience Research into Diagnostic and Treatment Biomarkers for ADHD.

Loo S, Lenartowicz A, Norman L, Michelini G Adv Neurobiol. 2024; 40:579-616.

PMID: 39562458 DOI: 10.1007/978-3-031-69491-2_20.


The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review.

Neuchat E, Bocklud B, Kingsley K, Barham W, Luther P, Ahmadzadeh S Neurol Int. 2023; 15(2):697-707.

PMID: 37218982 PMC: 10204383. DOI: 10.3390/neurolint15020043.


Treatment biomarkers for ADHD: Taking stock and moving forward.

Michelini G, Norman L, Shaw P, Loo S Transl Psychiatry. 2022; 12(1):444.

PMID: 36224169 PMC: 9556670. DOI: 10.1038/s41398-022-02207-2.


References
1.
Kobel M, Bechtel N, Weber P, Specht K, Klarhofer M, Scheffler K . Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol. 2008; 13(6):516-23. DOI: 10.1016/j.ejpn.2008.10.008. View

2.
Loo S, Bilder R, Cho A, Sturm A, Cowen J, Walshaw P . Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2016; 55(8):674-682.e1. PMC: 5003618. DOI: 10.1016/j.jaac.2016.04.020. View

3.
Janssen T, Bink M, Gelade K, van Mourik R, Maras A, Oosterlaan J . A Randomized Controlled Trial Investigating the Effects of Neurofeedback, Methylphenidate, and Physical Activity on Event-Related Potentials in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2016; 26(4):344-53. DOI: 10.1089/cap.2015.0144. View

4.
McCracken J, McGough J, Loo S, Levitt J, DelHomme M, Cowen J . Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry. 2016; 55(8):657-666.e1. PMC: 4976782. DOI: 10.1016/j.jaac.2016.05.015. View

5.
Biederman J, Spencer T, Wilens T . Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004; 7(1):77-97. DOI: 10.1017/S1461145703003973. View